Post by JHam on Jul 9, 2014 14:34:51 GMT
BrainStorm is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).
- In June 2014 BCLI raised $10.5M, bringing their cash total to around $14M
- Also in June they announced Tony Fiorino as new CEO
- In May 2014 they commenced a Phase II trial in the USA for ALS
- Anticipated up-list to a national index sometime this year
- Complete data for their Phase I ALS trial in Israel expected to be published in August 2014
- Other indications to be announced in 2014
Website: www.brainstorm-cell.com/
SEC Filings: www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001137883&owner=exclude&count=40&hidefilings=0
Clinical trials page: clinicaltrials.gov/ct2/show/study/NCT02017912?term=nurown+stemcell&rank=1
- In June 2014 BCLI raised $10.5M, bringing their cash total to around $14M
- Also in June they announced Tony Fiorino as new CEO
- In May 2014 they commenced a Phase II trial in the USA for ALS
- Anticipated up-list to a national index sometime this year
- Complete data for their Phase I ALS trial in Israel expected to be published in August 2014
- Other indications to be announced in 2014
Website: www.brainstorm-cell.com/
SEC Filings: www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001137883&owner=exclude&count=40&hidefilings=0
Clinical trials page: clinicaltrials.gov/ct2/show/study/NCT02017912?term=nurown+stemcell&rank=1